Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein cholesterol levels. Although statins increase serum PCSK9 levels, the effects of different types of statins on the serum PCSK9 levels have not been examined in detail. The purpose of the present study was to compare the effects of pitavastatin versus pravastatin on the serum PCSK9 levels. A total of 164 patients with coronary artery disease who were not receiving lipid-lowering therapy were randomly assigned to receive either 4 mg/day of pitavastatin (intensive lipid-lowering therapy) or 20 mg/day of pravastatin (moderate lipid-lowering therapy). The serum PCSK9 levels were measured before statin treatment and 8 months after therapy. A significantly greater reduction in low-density lipoprotein cholesterol was observed in the pitavastatin group (−41% vs −28%, p = 0.0001). The serum levels of total PCSK9 and heterodimer PCSK9 significantly increased from 192 to 249 ng/ml (37%, p <0.0001) and 147 to 206 ng/ml (78%, p <0.0001) in the pitavastatin group and from 192 to 249 ng/ml (39%, p <0.0001) and 143 to 201 ng/ml (65%, p <0.0001) in the pravastatin group, respectively. The increase in total and heterodimer PSCK9 did not differ between the 2 groups. No significant correlations were found between the percentage of changes in heterodimer PCSK9 and changes in the various lipid parameters in either group. In conclusion, significant increases in the total and heterodimer PSCK9 levels were observed at 8 months after treatment with pitavastatin and pravastatin; however, these increases did not differ between the 2 statins.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Molecular biology of PCSK9: its role in LDL metabolism.Trends Biochem Sci. 2007; 32: 71-77
- The proprotein convertases and their implication in sterol and/or lipid metabolism.Biol Chem. 2006; 387: 871-877
- PCSK9: a promising therapeutic target for dyslipidemias?.Trends Endocrinol Metab. 2006; 17: 79-81
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.J Lipid Res. 2007; 48: 763-767
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.J Clin Invest. 2006; 116: 2995-3005
- Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.J Biol Chem. 2004; 279: 50630-50638
- NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.J Biol Chem. 2004; 279: 48865-48875
- Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.Arterioscler Thromb Vasc Biol. 2004; 24: 1454-1459
- Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.J Lipid Res. 2010; 51: 1486-1495
- Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.Arterioscler Thromb Vasc Biol. 2006; 26: 1094-1100
- Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.J Lipid Res. 2008; 49: 394-398
- Genetic and metabolic determinants of plasma PCSK9 levels.J Clin Endocrinol Metab. 2009; 94: 2537-2543
- A new method for measurement of total plasma PCSK9: clinical applications.J Lipid Res. 2010; 51: 140-149
- Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis.Am Heart J. 2012; 163: 191-199
- Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.Biochem J. 2007; 406: 203-207
- Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.J Biol Chem. 2007; 282: 20799-20803
- Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.J Biol Chem. 2007; 282: 18602-18612
- Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.Transl Res. 2012; 160: 125-130
- The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.J Biol Chem. 2006; 281: 30561-30572
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.J Lipid Res. 2010; 51: 2714-2721
- Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.J Clin Endocrinol Metab. 2010; 95: 800-809
- Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.Atherosclerosis. 2012; 224: 454-456
- Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.J Am Coll Cardiol. 2012; 59: 1778-1784
Published online: February 22, 2013
Accepted: January 16, 2013
Received in revised form: January 16, 2013
Received: December 30, 2012
See page 1418 for disclosure information.
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.